Medication info
Jardiance Duo Extended-Release Tablet 25/1000 mg (Empagliflozin, Metformin)

Jardiance Duo Extended-Release Tablet 25/1000 mg (Empagliflozin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›25mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Hana Pharmaceutical Co., Ltd.
Appearance
Pink rectangular extended-release film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202501246 · Approved 2025.05.21 · Insurance code 657808410

Summary

Main use
Improvement of blood glucose control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
In antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000 mg. This drug should be taken once daily with the evening meal to reduce gastrointestinal adverse reactions caused by metformin. Take one tablet of this drug 10/1000 mg extended-release tablet or 25/1000 mg extended-release tablet once daily. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. When this drug is taken by patients who cannot achieve adequate glycemic control with metformin alone or in combination with other drugs such as insulin, the recommended initial total daily dose is empagliflozin 10 mg and the patient's current metformin dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. Patients switching from combination therapy with empagliflozin and metformin to this drug should receive their current doses of empagliflozin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. When this drug is coadministered with a sulfonylurea or insulin, a dose reduction of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. As dosage adjustment according to renal function may be necessary, assessment of renal function is recommended before treatment with this drug and periodically thereafter. No dose adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], if the drug is well tolerated and there are no other conditions that may increase the risk of lactic acidosis, it may be used with adjustment of the metformin hydrochloride dose as follows. - Since the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 ml/min/1.73m2, this drug should be discontinued immediately. In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.

Ingredients

Manufacturer
Hana Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in adults with type 2 diabetes mellitus

  • Difficulties in blood sugar control
  • cardiovascular disease
  • risk of cardiovascular events
View approved original text

This medication is used as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes who are appropriate for the combination of empagliflozin and metformin. Special care is needed for patients with type 2 diabetes whose blood sugar is not adequately controlled and who have cardiovascular disease, as they are at increased risk of cardiovascular events. Therefore, this medication serves as a treatment that helps manage blood sugar while also supporting cardiovascular health.

How to take

Adult dose

In antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000 mg. This drug should be taken once daily with the evening meal to reduce gastrointestinal adverse reactions caused by metformin. Take one tablet of this drug 10/1000 mg extended-release tablet or 25/1000 mg extended-release tablet once daily. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. When this drug is taken by patients who cannot achieve adequate glycemic control with metformin alone or in combination with other drugs such as insulin, the recommended initial total daily dose is empagliflozin 10 mg and the patient's current metformin dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. Patients switching from combination therapy with empagliflozin and metformin to this drug should receive their current doses of empagliflozin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. When this drug is coadministered with a sulfonylurea or insulin, a dose reduction of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. As dosage adjustment according to renal function may be necessary, assessment of renal function is recommended before treatment with this drug and periodically thereafter. No dose adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], if the drug is well tolerated and there are no other conditions that may increase the risk of lactic acidosis, it may be used with adjustment of the metformin hydrochloride dose as follows. - Since the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 ml/min/1.73m2, this drug should be discontinued immediately. In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.

Precautions

This medication is used to treat type 2 diabetes and helps lower blood sugar levels. However, it can rarely cause a serious condition known as lactic acidosis, so caution is warranted. Additionally, hypoglycemia may occur when used in conjunction with insulin or other diabetes medications. This medication should not be used in patients with significantly impaired kidney function or acute kidney problems. Patients with unstable cardiac function or acute heart failure should also refrain from using this medication. It is important to temporarily discontinue this medication before and after tests that use iodine-based contrast agents, and to resume only after confirming normal kidney function. Pregnant women or those with placental function issues should avoid using this medication. This medication can lead to fluid volume loss, so it should be used with caution in cases of dehydration, severe diarrhea, or vomiting. Patients with liver impairment should also avoid this medication, and excessive alcohol consumption is risky. Regular monitoring of kidney function and serum vitamin B12 levels is recommended during treatment. This medication may increase the risk of genital infections and urinary tract infections, so if any related symptoms arise, medical consultation should be sought immediately. Furthermore, hypoglycemic symptoms can occur, so caution should be exercised, especially after skipping meals or following exercise. This medication should be discontinued at least 48 hours prior to surgery, and resumed only after kidney function has recovered post-surgery. This medication should be swallowed whole without crushing, chewing, or breaking, and it is normal for the tablet shell to be excreted. Elderly patients or those with impaired kidney function may require dose adjustments and regular monitoring. In case of overdose, there is a risk of lactic acidosis, and prompt medical treatment should be sought. It is important to avoid acute or chronic alcohol consumption during treatment. Lastly, keep this medication out of reach of children and store it in its original container.

Side effects

  • Hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • decreased and deficiency of vitamin B12
  • ketoacidosis
  • lactic acidosis
  • nausea
  • vomiting
  • diarrhea
Show 110 more
  • abdominal pain
  • loss of appetite
  • constipation
  • abnormal liver function tests
  • hepatitis
  • altered taste
  • itching
  • rash
  • urticaria
  • erythema
  • angioedema
  • dysuria
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • decreased fluid volume
  • weight loss
  • chronic gastritis
  • cerebral infarction
  • soft tissue infection
  • pneumonia
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • vomiting
  • ischemic colitis
  • colon bleeding
  • appendiceal abscess
  • appendicitis
  • meningitis
  • chronic otitis media
  • peritonsillar abscess
  • pulmonary tuberculosis
  • acute pyelonephritis
  • sepsis
  • subcutaneous abscess
  • tubo-ovarian abscess
  • vestibular neuritis
  • headache
  • dizziness
  • cerebral infarction
  • intracranial aneurysm
  • fever
  • vascular stent stenosis
  • vascular stent thrombosis
  • increased alanine aminotransferase
  • increased aspartate aminotransferase
  • urinary stones
  • acute kidney injury
  • cervicitis
  • hyperglycemia
  • hyponatremia
  • diabetic foot
  • back pain
  • glaucoma
  • pathological myopia
  • retinal detachment
  • retinal vein occlusion
  • traction retinal detachment
  • epistaxis
  • asthma
  • exertional dyspnea
  • productive cough
  • allergic rhinitis
  • retained sputum
  • limb injury
  • skin laceration
  • contusion
  • rib fracture
  • concussion
  • corneal abrasion
  • falls
  • hand fracture
  • iliotibial band syndrome
  • open globe injury
  • pelvic fracture
  • road traffic accident
  • splenic injury
  • sternum fracture
  • angina
  • palpitations
  • Prinzmetal angina
  • coronary artery disease
  • tachycardia
  • atherosclerosis
  • deep vein thrombosis
  • diabetic vascular complications
  • peripheral artery occlusive disease
  • insomnia
  • anxiety
  • depression
  • sleep disorder
  • otalgia
  • positional vertigo
  • dizziness
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodule
  • vulvar pruritus
  • genital pruritus
  • cough
  • dyspnea

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air or moisture. It is important to maintain a storage temperature between 1 degree and 30 degrees Celsius.

Appearance and packaging

Appearance

Pink rectangular extended-release film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.